Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 18, 2026, 8:14 AM EDT
Active, not recruiting Not applicable Interventional Results available

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

NCT05236764
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection
Interventions
CliniMACS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 3 Interventional Results available

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT00462709
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Biological
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
48
States / cities
Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

NCT06012136
View directory record Official record
Conditions
HIV Infections
Interventions
VH4004280, Placebo, VH4011499
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 18, 2026, 8:14 AM EDT
Active, not recruiting Phase 1 Interventional

Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

NCT01961063
View directory record Official record
Conditions
AIDS-related Non-Hodgkin Lymphoma, AIDS-related Plasmablastic Lymphoma, AIDS-related Primary Effusion Lymphoma, HIV Infection
Interventions
busulfan, lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional Results available

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

NCT00884793
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir, Study NNRTI, Study PI
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional Results available

Two Approaches to Routine HIV Testing in a Hospital Emergency Department

NCT00502944
View directory record Official record
Conditions
HIV Infections
Interventions
Counselor-based HIV screening, Emergency staff member-based HIV screening
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
4,855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 4 Interventional

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

NCT00005764
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DCVax Plus Poly ICLC in Healthy Volunteers

NCT01127464
View directory record Official record
Conditions
HIV-1 Infection, HIV Infection, Healthy Volunteers
Interventions
DCVax-001, Poly-ICLC, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS

NCT05454514
View directory record Official record
Conditions
HIV Infections
Interventions
HiDO medication adherence platform, Automated Medication Platform with Video Observation, Time on Task
Device · Other
Lead sponsor
Charles Gellman
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
El Dorado Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Personalized Prevention for Couples: A 16-month Digital RCT

NCT05708014
View directory record Official record
Conditions
Hiv, HIV Infections, Sexually Transmitted Infection, Sexually Transmitted Diseases, Sexual Behavior, Risk Reduction
Interventions
Intervention LuvHub, Waitlist Control LuvHub
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older · Male only
Enrollment
778 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 18, 2026, 8:14 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

NCT06854029
View directory record Official record
Conditions
HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

NCT00001031
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 60 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

e-HERO: Ending the HIV Epidemic in Rural Oklahoma

NCT05664802
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
e-HERO: Ending the HIV Epidemic in Rural Oklahoma
Behavioral
Lead sponsor
Northern Arizona University
Other
Eligibility
17 Years to 29 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

NCT00002007
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Zidovudine, Sargramostim
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms

NCT00000707
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 18, 2026, 8:14 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

NCT01923311
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
EVG, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART

NCT00386971
View directory record Official record
Conditions
Hyperlipidemia, HIV Infections
Interventions
L-carnitine, placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 18, 2026, 8:14 AM EDT
Not listed Phase 4 Interventional

Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection

NCT04240509
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Emtricitabine / Tenofovir
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 4 Interventional

Nutrition Intervention in AIDS Wasting

NCT00006167
View directory record Official record
Conditions
HIV Wasting Syndrome
Interventions
oxandrolone, Progressive Resistance Training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Phase 4 Interventional

MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

NCT03226119
View directory record Official record
Conditions
HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma, HTLV I Associated Myelopathies
Interventions
MP Diagnostics HTLV Blot 2.4
Diagnostic Test
Lead sponsor
MP Biomedicals, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

NCT00490412
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 18, 2026, 8:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

NCT00490100
View directory record Official record
Conditions
Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
Interventions
Increlex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 20 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2015 · Synced Oct 18, 2026, 8:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection

NCT00001000
View directory record Official record
Conditions
HIV Infections
Interventions
Ampligen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1990
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 18, 2026, 8:14 AM EDT